Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton jelly-derived mesenchymal stem cells and exosomes (TC Erciyes University)
- Development stage
- Unknown
- Lead developer
- Erciyes University
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Wharton jelly-derived mesenchymal stem cells (WJ-MSCs) and their derived exosomes are being investigated by TC Erciyes University as a regenerative therapy for retinitis pigmentosa. WJ-MSCs are multipotent stem cells harvested from the umbilical cord matrix (Wharton's jelly). These cells and their exosomes are thought to exert therapeutic effects through the secretion of neurotrophic factors, immunomodulatory cytokines, and anti-apoptotic signals, which may help preserve photoreceptor function and slow retinal degeneration. In a Phase 2/3 clinical trial (NCT05413148), these biologics are administered via subtenon injection to evaluate their efficacy in improving or stabilizing visual functions in patients with retinitis pigmentosa. The stem cells and exosomes are processed in the university's Genome and Stem Cell GMP-certified laboratories.
- Other names
- WJ-MSCsWharton jelly-derived mesenchymal stem cellsWharton jelly-derived mesenchymal stem cell exosomesumbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on Wharton jelly-derived mesenchymal stem cells and exosomes (TC Erciyes University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton jelly-derived mesenchymal stem cells and exosomes (TC Erciyes University).